Business

Health tech startup Ryse Health raises $3.4M


Baltimore-based Ryse Health introduced Monday it has raised $3.4 million to offer tech-enabled office-based and digital care to sufferers with kind 2 diabetes.

Ryse Health, which additionally has places of work in Arlington, Virginia, was based by Erin Kane, MD, co-founder and chief medical officer, and Richard Gurley, MBA, co-founder and chief govt officer. Kane is a Harvard- and Johns Hopkins-trained doctor. She has led a number of care-delivery redesign initiatives, together with as an early chief of the Hopkins Capacity Command Center and a GW COVID-19 distant monitoring program. She additionally has expertise as a McKinsey administration guide and a deep understanding of well being care operations. Gurley was a frontrunner at two profitable value-based, tech-enabled well being care providers startups, Evolent Health and WelbeHealth. He has served as an adviser to seven main well being care development corporations, together with Doctor on Demand, Modern Fertility and Vera Whole Health. He additionally has prior expertise in McKinsey well being payer/supplier follow and the Tennessee state authorities.

Ryse Health’s know-how platform features a steady glucose monitor (CGM) and a customized app to synthesize information, help self-management, and facilitate easy communication. Their care workforce includes well being coaches, endocrinologists, and a broad care workforce of registered dieticians (RDs), licensed diabetes care and training specialists (CDCESs), and licensed medical social staff (LCSWs) to assist sufferers navigate the psychosocial obstacles to overcoming continual illness.

The firm’s lead investor is W Health Ventures with different well being care organizations reminiscent of LifeBridge Health, Healthworx (the innovation and funding arm of CareFirst BlueCross BlueShield), Shantanu Agrawal, MD, chief well being officer of Anthem BlueCross BlueShield; John Wray, interim CEO of Opala; and Kelly Close, a diabetes affected person advocate.





Source hyperlink

Leave a Reply

Your email address will not be published.

close